MedTrace Logo

Investigating the Bioavailability of Broccoli Extract Supplements

NCT07564674 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-07

No results posted yet for this study

Summary

The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention.

Participants will:

* consume 3 different versions of broccoli extract supplements (glucoraphanin will range from 35-70 mg)
* complete 3 separate 24 hour study cycles
* submit blood and urine samples for 24 hours
* follow diet restrictions (no cruciferous vegetables or condiments or phytochemical/herbal supplements for 1 week prior to and during each study cycle)

Conditions

  • Diet, Healthy

Interventions

DIETARY_SUPPLEMENT

Avmacol Extra Strength with coating - 1 tablet

Participants will swallow by mouth 1 tablet Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)

DIETARY_SUPPLEMENT

Avmacol chewable wafer - 2 tablets

Participants will chew and swallow by mouth 2 wafers Avmacol chewable wafers (30 mg glucoraphanin per wafer)

DIETARY_SUPPLEMENT

Avmacol Extra Strength with coating - 2 tablets

Participants will swallow by mouth 2 tablets Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)

Sponsors & Collaborators

  • Oregon State University

    lead OTHER

Principal Investigators

  • Emily Ho, PhD · Oregon State University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-09-30
Completion
2028-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07564674 on ClinicalTrials.gov